Vyome Holdings, Inc (HIND) stock
Close on Nov 11, 2026Market cap $11.02MP/E –Yield –
Vyome Holdings, Inc saw revenue fall 55.6% to $153.10K over the twelve months to Sep 30, 2026. At the latest close the market valued the company at $11.02M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $11.02M
- P/E ratio
- –
- Price to sales
- 84.94
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $153.10K
- Net income
- -$3.76M
- EPS, diluted
- -$4.86
- Diluted shares
- 7M
Trading
- Next earnings
- Nov 18, 2026 (estimated, during market hours)
- Previous close
- $1.54
- Open
- $1.58
- Day's range
- $1.53 – $1.72
- Volume
- 11,775
- Average volume (20 days)
- 12,975
- Beta (5 years)
- 1.56
- 52-week range
- $1.53 – $5.88
- RSI (14 days)
- 29.6
- Volatility (1 year)
- 75.3%
- Relative volume
- 0.89×
- WACC
- 12.7%
Market cap history
Month-end market cap since 2017, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | HIND | S&P 500 | Difference | HIND per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -24.9% | -2.4% | −22.5 pts | ||
| 3 months | -30.2% | -1.2% | −29.1 pts | ||
| Year to date | -54.4% | +12.3% | −66.7 pts | ||
| 1 year | -70.4% | +12.4% | −82.9 pts | ||
| 3 years | -99.9% | +78.8% | −178.7 pts | -89.6% | +21.4% |
| 5 years | -100.0% | +75.2% | −175.2 pts | -92.6% | +11.9% |
| 10 years | -100.0% | +311.1% | −411.1 pts | -83.2% | +15.2% |
Thirteen years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Vyome filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- Update
- Update
- Update
About Vyome
Pharmaceutical Preparations
Vyome Holdings, Inc. is a clinical-stage specialty pharmaceutical company focused on developing therapies for immuno-inflammatory and rare diseases with significant unmet needs. Operating through biotechnology and pharmaceutical segments, the company primarily develops repurposed molecules for orphan conditions. Its biotechnology pipeline includes VT-1953, a topical gel being evaluated for treating symptoms of malodorous malignant fungating wounds in advanced cancer patients, and VT-1908, an ophthalmic drop program under development for steroid-sparing anterior uveitis. Through its pharmaceutical segment, the company develops topical antifungal products utilizing its Molecular Replacement Therapeutics platform, which are licensed to commercial partners for target patient populations.
Company profile, executives and historyVyome stock: common questions
What is Vyome's stock price?
HIND closed at $1.57 on Nov 11, 2026, up 1.95% on the day. Over the past 52 weeks it traded between $1.53 and $5.88.
What is Vyome's market cap?
Vyome was worth $11.02M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is HIND's P/E ratio?
Vyome lost money over fiscal 2025 (diluted EPS -$4.86), so it has no meaningful P/E ratio.
How much revenue does Vyome make?
Vyome reported revenue of $153.10K for the twelve months to Sep 30, 2026, down 55.6% from a year earlier.
Does Vyome pay a dividend?
No. Vyome has not paid a cash dividend over the last twelve months.
When does Vyome report earnings next?
Vyome is expected to report Q3 FY2026 results on Nov 18, 2026, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has HIND stock performed over the past year?
Including dividends, HIND returned -70.4% over the past year, against +12.4% for the S&P 500.
How many HIND shares are sold short?
0M shares were sold short at the latest FINRA report, 0.28% of the float, or 1.6 days of average trading volume.
Who are Vyome's competitors?
Companies most similar to Vyome by business, industry and size include SNGX, LSTA, IXHL, RDHL, KZIA.
See a number that looks wrong?